Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jason Kim

Pain Medicine Issaquah, WA Medical Doctor

NPI 1265534036 CMS profile 570569

22510 Se 64Th Pl, Suite 120, Issaquah, WA 98027

Open in the dashboard

General payments

$7,005

87 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jason Kim of Issaquah, WA is reported in the CMS Open Payments database as having received $7,005 across 87 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 73rd percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,074 10
2024 General $1,648 16
2023 General $353 3
2022 General $966 10
2021 General $793 8
2020 General $139 5
2019 General $2,033 35

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jason Kim
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Jason Kim were reported at $1,074. Among 2,779 Pain Medicine profiles paid that year, the median was $458 and the middle half received between $124 and $1,401.

Show as a table
Year Jason Kim Pain Medicine median Middle half National median
2019 $2,033 $498 $126–$1,682 $163
2020 $139 $284 $80–$910 $114
2021 $793 $399 $112–$1,219 $132
2022 $966 $455 $137–$1,484 $149
2023 $353 $484 $128–$1,495 $160
2024 $1,648 $498 $131–$1,540 $164
2025 $1,074 $458 $124–$1,401 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. SI-BONE, Inc. $1,586 11 payments
  2. Medtronic USA, Inc. $1,489 11 payments
  3. Medtronic, Inc. $928 11 payments
  4. Globus Medical, Inc. $922 7 payments
  5. MML US, Inc. $918 8 payments
  6. Stryker Corporation $630 15 payments
  7. Nevro Corp. $174 8 payments
  8. Boston Scientific Corporation $151 8 payments
  9. Abbott Laboratories $96 2 payments
  10. SPR Therapeutics, Inc $29 1 payment
  11. Other $82 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $3,776 13 payments
  2. Food and Beverage $3,228 74 payments
Products named General payments · program years 2019–2025
  1. IFUSE IMPLANT SYSTEM $1,299 5 payments
  2. INTERSTIM $1,270 7 payments
  3. Senza $922 7 payments
  4. ReActiv8 $918 8 payments
  5. INTELLIS $697 4 payments
  6. ENTELLUS - XPRESS ENT DILATION SYSTEM $266 11 payments
  7. PROPHECY $257 1 payment
  8. VECTRIS $200 3 payments
  9. INTELLIS ADAPTIVESTIM $153 4 payments
  10. GENERAL PAIN MANAGEMENT $97 5 payments
  11. Other $621 25 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 16 drugs

Part D claims

676

Median for Pain Management: 951

Drug cost

$33,250

Median for Pain Management: $26,034

Branded share of claims

37.6%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycontin Oxycodone Hcl Brand 38 $22,706
Oxycodone Hcl Generic 144 $1,967
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 124 $1,611
Buprenorphine Generic 15 $1,431
Fentanyl Generic 11 $969
Morphine Sulfate Er Morphine Sulfate Brand 22 $911
Buprenorphine Hcl Generic 16 $816
Gabapentin Generic 56 $755
Hydromorphone Hcl Generic 54 $548
Tramadol Hcl Generic 73 $427

The 10 drugs with the highest cost, of 16 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$246,915

Of which drugs: $26,296

Medicare patients

340

Average age 75

Services billed

7,007

193 women, 147 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 70%
Ischemic heart disease 24%
Depression 24%
Osteoporosis 21%
Diabetes 19%
Chronic kidney disease 16%
Atrial fibrillation 15%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg J0702 Office 285 4,708 $26,125
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 26 260 $23

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

87 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record